autarkize | $2,502,492 | (Nov 1, 2024)
Keel | $5,933,454 | (Nov 1, 2024)
Decart | $21,000,000 | (Nov 1, 2024)
ArrePath
United States
- Princeton, New Jersey
- 03/03/2022
- Seed
- $20,000,000
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.
Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.
- Industry Biotechnology Research
- Website https://arrepath.com/
- LinkedIn https://www.linkedin.com/company/arrepath/about/
Related People
Lloyd PayneFounder
United Kingdom -
Drug Discovery executive and leader, AMR and anti-infectives specialist, CEO at ArrePath Inc., a Princeton University spin-out biotech company combining ML- and imaging-technologies to discovery and develop new classes of anti-infectives.
Advisor to the Novo REPAIR Impact Fund and the AMR Action Fund.
Formerly Head of Anti-infectives at Evotec SE and founding CEO of specialist Anti-infectives company, Euprotec (founded 2008, built and successfully sold to Evotec, 2014).
Working with companies and organisations dedicated to the discovery and development of new anti-infective therapies and vaccines across multiple sectors, including Biotech, CRO, academia, Public-Private Partnerships, VC / Investors, and charities.
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MOTORMIA | $8,000,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Ataraxis AI | $4,000,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)
LINGO | $2,250,000 | (Nov 1, 2024)
ContraForce | $3,250,000 | (Nov 1, 2024)